Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts. Show more

Location: 451 D Street, Boston, MA, 02210, United States | Website: https://elicio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

123.5M

52 Wk Range

$3.34 - $9.99

Previous Close

$7.72

Open

$7.80

Volume

13,520

Day Range

$7.72 - $7.89

Enterprise Value

110.8M

Cash

18.35M

Avg Qtr Burn

-8.766M

Insider Ownership

45.12%

Institutional Own.

10.45%

Qtr Updated

03/31/25